Downloading...
Download

CMPS

Psychedelic Stocks About to Trip! 100%+ UpsidesPsychedelic Stocks About to Trip! 🍄 RFK Jr. has been named the top health official in Trump's administration, and he's known for his stance against big pharma and preference for natural products like psychedelics. This could be a game-changer for psychedelic stocks! In this video analysis, I dive deep into the potential impact RFK Jr. could have on key psychedelic stocks: AMEX:CYBN , NASDAQ:CMPS , NASDAQ:ATAI , and $MNMD. These stocks are poised for significant movement, and you won't want to miss out on the insights and strategies I share. Not financial advice. 👇
NASDAQ:ATAILong
by RonnieV29
14
Compass Pathways Wave Analysis: Huge Moves aheadCompass Pathways appears to have completed an impulsive 5-wave move to the upside, signaling significant strength in its recent price action. The peak of this move, reaching $12.75, is notably identified as the B wave within an extended flat correction, potentially forming part of a larger 5-wave pattern. In anticipation of a corrective phase, I anticipate a retracement towards the 0.618 - 0.65 Fibonacci ratio. This level coincides with a point of demand established in May 2022, which has historically served as a robust support level. Therefore, I am targeting a correction to the range of $6.86-7.06, presenting a compelling buying opportunity. This represents a potential decrease of approximately 30.7% to 29.1% from the current price of $9.90. Looking ahead, my projections for subsequent waves are as follows: Low: $21.07 (+112.8%) Medium: $29.68 (+199.8%) High: $41.80 (+322.2%) Moonshot: $120 (+1,111.1%) It's essential to note that the realization of these targets will be contingent upon the outcome of Compass Pathways' significant psilocybin phase 3 trial, slated for release by year-end. Regardless of the trial's results, I anticipate a substantial increase in price leading up to the release date, driven by market anticipation and sentiment. In summary, while Compass Pathways demonstrates considerable strength in its recent price movements, caution is advised as the stock may undergo a corrective phase towards identified support levels before potentially resuming its upward trajectory, influenced by the impending trial results.
NASDAQ:CMPSLong
by joshuashepherd877
long $CMPSLooks like the MACD is still heading down but curling up. RSI is bottoming out as it reaches an important level of support. I think the risk reward at the $28 level is optimal. If you have a high risk tolerance, buy now. Shrooms are already decriminalized in Denver and are about to be in Detroit. The TAM which was initially an imaginative number is now becoming real for Compass Pathways. Go long CMPS www.freep.com Looks ready to find a floor and launch on the weekly chart.
NASDAQ:CMPSLong
by EBITDAtiger
2
COMPASS Pathways plcCOMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom. Are revenue and earnings forecast to grow? Earnings are forecast to decline by an average of 15.5% per year for the next 3 years Section 4.1 Fail Are they forecast to achieve profitability? Currently unprofitable and not forecast to become profitable over the next 3 years Section 4.1 Pass Are they in a good financial position? They have sufficient cash for at least 1 year of operations Section 6.4 Pass Is their dividend sustainable? They do not pay a dividend Section 7.0 Pass Is their share price liquid and stable? Share price has been stable over the past 3 months Section 2.1 Pass Do they have sufficient financial data available? They have sufficient analyst coverage Section 4.0 Pass Are there any concerning recent events? No concerning events detected Section 2.1 Pass Do they have a meaningful market capitalization? Market cap is meaningful ($1B) Section 10.0 Pass Do they have negative shareholders equity? CMPS does not have negative shareholders equity.
NASDAQ:CMPSLong
by Skinwah
Another swing trade idea for you! 😎Hey guys! Another trading idea for you! CMPS looks interesting for a swing trade! In the 4h chart it is doing a good bullish pattern (harami) just above the 20ma and the 36.36 (red line). The purple area is a resistance area, as the daily chart suggests. CMPS just hit the 20ma in the daily chart too, along with the 20ma. If it loses these points, then we must wait for another entry point, but if it triggers the harami in the 4h chart, it has good chances of breaking the purple area. This would be a pivot point for CMPS, that could lead it to higher levels, maybe the 50s! Let’s watch CMPS closely! 👀 If you liked this trading idea, remember to click on the “Follow” button to get more trading ideas like this, and if you agree with me, click on the “Agree” button 😉. See you soon, Melissa.
NASDAQ:CMPS
by UnknownUnicorn21312077
Time to make money on magic mushroomsFor those that follow my analysis regularly, you know that I do not cover penny stocks or anything thinly traded. The reason for this is because it's simply not necessary to generate big returns trading penny stocks. I would MUCH rather trade options on large cap stocks any day. No question about it. I also don't rely on fundamentals because I am a technical trader, however, all of the stocks I pick to trade are considered fundamentally strong by all metrics (consistently strong EPS growth / rapidly growing revs /high RS in their respective category, etc). But now I am looking at these penny stocks in the magic mushroom sector. Medicine using psilocybin (active ingredient in magic mushrooms) is intriguing because it could be a powerful theme . I love finding themes that haven't really hit mainstream yet (think weed stocks in 2017, crypto in 2016, Electric Vehicles, SaaS, etc). Themes generate buzz and stir hype, which is key for parabolic moves. Of all shroom stocks I've looked at, MindMed (chart above) looks best to me on a technical basis. It has a clear invalidation point (so risk could be measured) and it just broke out. It was the first psychedelic medicine company to list on the Canadian exchange in March 2020. Kevin O'Leary from Shark Tank is invested in it. I always found Kevin to be the savviest in the room, so the fact that he's involved says a lot to me. Click here for their investor deck or click here for the website. Here are two other companies in the space: 2) Compass Pathways, backed by the Facebook investor Peter Thiel: 3) And Champignon Brands: I don't like buying dips like these that don't have enough history, so the only one I'll be buying in small size (no more than 4% of my capital) is MindMed. As someone that's done shrooms in Amsterdam, in the mountains while camping, and several other amazing trips, I am a big believer in the positive outcomes magic mushrooms could bring. Bitcoin actually clicked while I was on a shroom trip in 2015. Fun times :)
MLong
by Lanmar
33